These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 12792751

  • 1. A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.
    Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno T, Machida S, Sato I.
    Oncol Rep; 2003; 10(4):951-5. PubMed ID: 12792751
    [Abstract] [Full Text] [Related]

  • 2. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P.
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [Abstract] [Full Text] [Related]

  • 3. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T, Menczer J, Bernstein RM, Shpigel S, Matcejevsky D, Inbar MJ, Golan A, Grisaru D, Levy T.
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [Abstract] [Full Text] [Related]

  • 4. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 5. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
    Vapattanawong P.
    J Med Assoc Thai; 2006 Sep 01; 89(9):1357-61. PubMed ID: 17100369
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T, Alshaikh G, Hopkins L, Faught W, Fung MF.
    Ann Surg Oncol; 2006 Dec 01; 13(12):1711-6. PubMed ID: 17009146
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C.
    Anticancer Res; 2000 Dec 01; 20(5C):4047-50. PubMed ID: 11268499
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF, Liu FY, Chen FJ, Feng YL.
    Ai Zheng; 2007 Apr 01; 26(4):431-4. PubMed ID: 17430668
    [Abstract] [Full Text] [Related]

  • 11. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug 01; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 12. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J.
    Gynecol Oncol; 2010 Mar 01; 116(3):301-6. PubMed ID: 19945740
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I, Lindborg K, Sorbe B.
    Oncol Rep; 2007 Nov 01; 18(5):1249-56. PubMed ID: 17914581
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, Kuhn W, Rudlowski C.
    Cancer Chemother Pharmacol; 2010 May 01; 66(1):203-7. PubMed ID: 20204367
    [Abstract] [Full Text] [Related]

  • 15. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
    Misawa A, Yasuda M.
    Gan To Kagaku Ryoho; 2006 Oct 01; 33(10):1445-52. PubMed ID: 17033235
    [Abstract] [Full Text] [Related]

  • 16. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y.
    Oncol Rep; 2011 Apr 01; 25(4):1131-8. PubMed ID: 21249319
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A, Lianos E, Internos I, Papaxoinis G, Tselepatiotis E, Ziras N, Athanasiou AE.
    J BUON; 2010 Apr 01; 15(4):647-51. PubMed ID: 21229624
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients.
    Mayerhofer K, Bodner K, Saletu B, Bodner-Adler B, Anderer P, Hefler L, Schindl M, Kaider A, Leodolter S, Kainz C.
    Anticancer Res; 2001 Apr 01; 21(1B):803-8. PubMed ID: 11299847
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group.
    Cancer; 2008 May 15; 112(10):2202-10. PubMed ID: 18348296
    [Abstract] [Full Text] [Related]

  • 20. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 15; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.